-
iPSC TechnologyContact Information
- Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)
- Business Registration No.: 109-86-37282
- CEO: Choongseong Han
- Tel: +82-2-2088-8886
- Fax: +82-2-2088-8884
- E-mail: support@nexel.co.kr
-
News
- Home
- News
- News
News
Total 20
NEXEL "iPSC-derived cardiomyocytes, Go to space on Space X"
NEXEL and Japan's CMIC have strategic meeting, "A quick step toward targeting overseas markets"
‘hiPSC’ Nexel attracts 15 billion won in pre-IPO “expanding overseas expansion”
NEXEL-CROEN has signed an MOU on technology business for non-clinical evaluation of drugs
'Curi Bio' Announces Exclusive Distribution and Services Partnership with 'NEXEL'
“Next Year’s IPO Goal... We’ll be Leading the iPSC Market,” Says Choongseong Han, CEO of NEXEL
Bio Venture Company NEXEL Takes its First Step toward being Listed on KOSDAQ After Being Certified as a Company Specializing in Materials, Parts, and Equipment (MPE)
NEXEL earns Korean Industry Technology certification for So-Bu-Jang specialization from KEIT
NEXEL Earns the First ISO/IEC 17025:2017 Accreditation for iPSC-derived Cardiomyocyte-based Cardiac Safety Testing
Celogics highlights its iPSC derived Cardiomyocytes at the Society of Toxicology (SOT) Annual Meeting and Tox Expo